Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Risk & Volatility
Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Mirum Pharmaceuticals and BioLineRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
Mirum Pharmaceuticals presently has a consensus target price of $155.56, indicating a potential upside of 67.49%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than BioLineRx.
Valuation & Earnings
This table compares Mirum Pharmaceuticals and BioLineRx”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $670.78 million | 9.04 | -$23.36 million | ($15.47) | -6.00 |
| BioLineRx | $1.39 million | 4.22 | -$1.17 million | ($1.69) | -0.70 |
BioLineRx has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mirum Pharmaceuticals and BioLineRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -134.75% | -97.25% | -12.59% |
| BioLineRx | -502.08% | -34.80% | -18.27% |
Institutional & Insider Ownership
1.6% of BioLineRx shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Mirum Pharmaceuticals beats BioLineRx on 9 of the 15 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
About BioLineRx
BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
